NASDAQ:RKDA - Arcadia Biosciences Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$5.53 -0.18 (-3.15 %)
(As of 08/16/2018 02:12 AM ET)
Previous Close$5.71
Today's Range$5.32 - $5.78
52-Week Range$3.60 - $66.56
Volume85,878 shs
Average Volume482,647 shs
Market Capitalization$14.76 million
P/E Ratio-0.81
Dividend YieldN/A
Beta-5.77
Arcadia Biosciences logoArcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaboration with Dow AgroSciences to develop and commercialize enhanced wheat quality trait. The company was founded in 2002 and is headquartered in Davis, California.

Receive RKDA News and Ratings via Email

Sign-up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
SymbolNASDAQ:RKDA
CUSIPN/A
Phone530-756-7077

Debt

Debt-to-Equity RatioN/A
Current Ratio10.26
Quick Ratio10.16

Price-To-Earnings

Trailing P/E Ratio-0.81
Forward P/E Ratio-1.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.03 million
Price / Sales3.40
Cash FlowN/A
Price / CashN/A
Book Value$3.75 per share
Price / Book1.47

Profitability

EPS (Most Recent Fiscal Year)($6.86)
Net Income$-15,700,000.00
Net Margins-928.72%
Return on Equity-360.93%
Return on Assets-111.00%

Miscellaneous

Employees42
Outstanding Shares2,480,000
Market Cap$14.76 million

Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences Inc (NASDAQ:RKDA) issued its quarterly earnings data on Friday, August, 10th. The basic materials company reported ($2.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.29) by $0.73. The basic materials company earned $0.44 million during the quarter, compared to the consensus estimate of $0.20 million. Arcadia Biosciences had a negative return on equity of 360.93% and a negative net margin of 928.72%. View Arcadia Biosciences' Earnings History.

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Arcadia Biosciences.

What price target have analysts set for RKDA?

2 analysts have issued 1-year price targets for Arcadia Biosciences' shares. Their forecasts range from $20.00 to $20.00. On average, they expect Arcadia Biosciences' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 261.7% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.

What is the consensus analysts' recommendation for Arcadia Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.

Who are some of Arcadia Biosciences' key competitors?

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the folowing people:
  • Mr. Rajendra Ketkar, Pres, CEO & Director (Age 64)
  • Mr. Matthew T. Plavan, CFO & Sec. (Age 54)
  • Dr. Zhongjin Lu Ph.D., VP of Product Devel. (Age 52)
  • Ms. Sarah Reiter, Chief Commercial Officer (Age 46)

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Has Arcadia Biosciences been receiving favorable news coverage?

News articles about RKDA stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arcadia Biosciences earned a daily sentiment score of 0.19 on Accern's scale. They also assigned headlines about the basic materials company an impact score of 45.43 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Arcadia Biosciences.

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (2.22%) and Ardsley Advisory Partners (1.01%). Company insiders that own Arcadia Biosciences stock include Eric J Rey and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.

Which major investors are buying Arcadia Biosciences stock?

RKDA stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Ardsley Advisory Partners. View Insider Buying and Selling for Arcadia Biosciences.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $5.53.

How big of a company is Arcadia Biosciences?

Arcadia Biosciences has a market capitalization of $14.76 million and generates $4.03 million in revenue each year. The basic materials company earns $-15,700,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Arcadia Biosciences employs 42 workers across the globe.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]


MarketBeat Community Rating for Arcadia Biosciences (NASDAQ RKDA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote "Outperform" if you believe RKDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.